Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | CETP | P11597 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18334416 | 0.77 | PTK2B (0.38) | NPC1POLBPTK2BHIF1ATSHR | |
| SCHEMBL18334414 | 0.76 | NPC1 (0.40) | NPC1POLBPTK2BTSHRFDPS | |
| SCHEMBL981692 | 0.76 | TSHR (0.45) | NPC1POLBHIF1ATSHRALDH1A1 | |
| SCHEMBL28094950 | 0.75 | INPPL1 (0.39) | CETPALDH1A1 | |
| SCHEMBL982245 | 0.73 | TSHR (0.45) | NPC1POLBHIF1ATSHRALDH1A1 | |
| SCHEMBL816996 | 0.73 | ESR1 (0.32) | — | |
| SCHEMBL984264 | 0.71 | ALDH1A1 (0.44) | TSHRALDH1A1 | |
| SCHEMBL8555216 | 0.71 | PIN1 (0.41) | NPC1POLBPTK2BTSHRALDH1A1 | |
| SCHEMBL982025 | 0.70 | ALDH1A1 (0.42) | TSHRALDH1A1 | |
| SCHEMBL982739 | 0.70 | ALDH1A1 (0.42) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044091-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2256124-A1 | Phospho-indoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-1961757-B1 | Phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-7534809-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1799696-B1 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1961757-A1 | Phosphoindoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1799696-A2 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006054182-A9 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX CAYMAN LTD | 2006-08-17 | — | — | WO | disclosed |
| WO-2006054182-A2 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDO1, PPP5C, INMT | NPC1 3653/4885POLB 712/4885PTK2B 527/4885 |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDO1, PPP5C, INMT | NPC1 3653/4885POLB 712/4885PTK2B 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.